Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical has secured $150 million in firm commitments through a single-tranche institutional placement at $3.80 per share, cornerstoned by global long-only institutional investors and strongly supported by existing shareholders, with overall dilution limited to 3.86% by repurposing shares previously issued to Alpha Investment Partners. The funds will primarily accelerate commercialisation of its CT:VQ™ lung imaging product in the U.S., expanding sales, marketing, customer support and R&D, lifting pro forma cash to more than $200 million and giving the company balance-sheet capacity to drive CT:VQ™ adoption at elite U.S. centres, pursue profitability, and reinforce its ambition to make the technology a new standard in pulmonary imaging, while the CEO and CFO have signalled confidence by exercising options and increasing their shareholdings.
The most recent analyst rating on (AU:4DX) stock is a Sell with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is an Australian respiratory imaging technology company listed on the ASX that develops advanced lung imaging solutions, notably its CT:VQ™ platform. The company focuses on commercialising its products in the U.S. market, targeting leading academic medical centres and health systems, and leverages strategic partnerships, including with Philips, to strengthen its position in pulmonary imaging.
Average Trading Volume: 4,635,655
Technical Sentiment Signal: Buy
Current Market Cap: A$2.3B
For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.